CGTX (Cognition Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CGTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | ELLEN B RICHSTONE | Director | A | — | — |
| 2026-06-22 | Jack A. Khattar | Director | A | — | — |
| 2026-06-22 | Peggy Wallace | Director | A | — | — |
| 2026-06-22 | Brett P Monia | Director | A | — | — |
| 2026-06-22 | BIOS Advisors GP, LLC | Director | A | — | — |
| 2026-05-04 | John Brendan Doyle | Chief Financial Officer | F | — | — |
| 2026-04-20 | Lisa Ricciardi | CEO & President | Buy | — | — |
| 2026-04-20 | John Brendan Doyle | Chief Financial Officer | Buy | — | — |
| 2026-04-20 | Anthony Caggiano | Chief Medical Officer | Buy | — | — |
| 2026-02-18 | Anthony Caggiano | Chief Medical Officer | F | — | — |
| 2026-02-18 | John Brendan Doyle | Chief Financial Officer | F | — | — |
| 2026-02-18 | Lisa Ricciardi | CEO & President | F | — | — |
| 2026-02-05 | John Brendan Doyle | Chief Financial Officer | MIXED | — | — |
| 2026-02-05 | Anthony Caggiano | Chief Medical Officer | MIXED | — | — |
| 2026-02-05 | Lisa Ricciardi | CEO & President | MIXED | — | — |
| 2025-12-22 | Anthony Caggiano | Chief Medical Officer | MIXED | — | — |
| 2025-12-22 | Lisa Ricciardi | CEO & President | MIXED | — | — |
| 2025-12-22 | John Brendan Doyle | Chief Financial Officer | MIXED | — | — |
| 2025-09-23 | Aaron G.L. Fletcher | Director | M | — | — |
| 2025-07-31 | John Brendan Doyle | Chief Financial Officer | MIXED | — | — |
| 2025-07-31 | Anthony Caggiano | Chief Medical Officer | MIXED | — | — |
| 2025-07-31 | Lisa Ricciardi | CEO & President | MIXED | — | — |
| 2025-06-23 | Brett P Monia | Director | A | — | — |
| 2025-06-23 | Peggy Wallace | Director | A | — | — |
| 2025-06-23 | ELLEN B RICHSTONE | Director | A | — | — |
| 2025-06-23 | Jack A. Khattar | Director | A | — | — |
| 2025-06-20 | Cavu Advisors, LLC | Director | A | — | — |
| 2025-06-20 | BIOS Fund II QP, LP | Director | A | — | — |
| 2025-05-02 | John Brendan Doyle | Chief Financial Officer | F | — | — |
| 2025-02-18 | Anthony Caggiano | Chief Medical Officer | F | — | — |
| 2025-02-18 | John Brendan Doyle | Chief Financial Officer | F | — | — |
| 2025-02-18 | Lisa Ricciardi | CEO & President | F | — | — |
| 2025-02-04 | Anthony Caggiano | Chief Medical Officer | MIXED | — | — |
| 2025-02-04 | Lisa Ricciardi | CEO & President | MIXED | — | — |
| 2025-02-04 | John Brendan Doyle | Chief Financial Officer | A | — | — |
| 2024-06-11 | Peggy Wallace | Director | A | — | — |
| 2024-06-11 | Brett P Monia | Director | A | — | — |
| 2024-06-11 | ELLEN B RICHSTONE | Director | A | — | — |
| 2024-06-11 | Jack A. Khattar | Director | A | — | — |
| 2024-06-11 | Cavu Advisors, LLC | Director | A | — | — |
| 2024-06-11 | BIOS Capital Management, LP | Director | A | — | — |
| 2024-05-03 | John Brendan Doyle | Chief Financial Officer | F | — | — |
| 2024-03-14 | Lisa Ricciardi | CEO & President | Buy | — | — |
| 2024-02-20 | Lisa Ricciardi | CEO & President | A | — | — |
| 2024-02-20 | John Brendan Doyle | Chief Financial Officer | A | — | — |
| 2024-02-20 | Anthony Caggiano | Chief Medical Officer | A | — | — |
| 2024-02-09 | Anthony Caggiano | Chief Medical Officer | F | — | — |
| 2024-02-09 | Lisa Ricciardi | CEO & President | F | — | — |
| 2023-11-13 | Cavu Advisors, LLC | Director | A | — | — |
| 2023-11-13 | BIOS Memory SPV I, LP | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,445,920 | — |
| — | 10%+ Owner | 2,210,377 | — |
| — | CEO & President | 1,754,702 | — |
| — | Director | 1,430,014 | — |
| — | Chief Medical Officer | 874,906 | — |
| — | Chief Financial Officer | 618,942 | — |
| — | Director | 475,155 | — |
| — | 10%+ Owner | 418,926 | — |
| — | Director | 418,926 | — |
| — | Director | 399,748 | — |
| — | Director | 385,248 | — |
| — | Director | 358,248 | — |
| — | Director | 332,733 | — |
| — | 10%+ Owner | 255,765 | — |
| — | 10%+ Owner | 245,029 | — |
| — | Director | 159,527 | — |
| — | Director | 111,461 | — |
| — | Director | 83,500 | — |
| — | 10%+ Owner | 78,298 | — |
| — | Director | 73,500 | — |
| — | Director | 73,500 | — |
| — | Director | 52,417 | — |
| — | Director | 34,238 | — |
| — | Chief Financial Officer | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CGTX quote page; the site-wide leaderboard is on the insider transactions hub.